Sugi Predict

Sugi Predict / Compounds / SCHEMBL425784

SCHEMBL425784

SCHEMBL425784

O=CNS(=O)(=O)c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ KDM4E B2RXH2 2/20 0.51
▸ ALDH1A1 P00352 3/20 0.49
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CACNA1B Q00975 1/20 0.47
▸ APBA1 Q02410 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ PKM P14618 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NFKBIA P25963 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ GLO1 Q04760 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740403 0.82 CYP2D6 (0.56) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL7455235 0.79 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL24254325 0.79 CYP2D6 (0.67) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL10490753 0.78 CYP2D6 (0.51) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL1863910 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL1164889 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL28978077 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL8232303 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL4433902 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL28314029 0.75 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216238-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck Frosst Canada & Co. (CA) 2002-06-26 — — EP claimed
WO-2001019814-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA & CO. (CA) 2001-03-22 — — WO claimed
EP-2314593-B1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARM INC (US) 2016-05-04 — — EP disclosed
US-8835461-B2 Substituted 3-hydroxy-4-pyridone derivative SHIONOGI & CO., LTD. (JP) 2014-09-16 — — US disclosed
EP-2412708-A1 SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE Shionogi&Co., Ltd. (JP) 2012-02-01 — — EP disclosed
US-20120022255-A1 SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2012-01-26 — — US disclosed
US-20080300138-A1 Dioxazinyl-Substituted Thienylsulphonylaminocarbonyl Compounds GESING ERNST R F 2008-12-04 — — US disclosed
US-20080300138-A1 Dioxazinyl-Substituted Thienylsulphonylaminocarbonyl Compounds GESING ERNST R F 2008-12-04 — — US disclosed
US-20080300138-A1 Dioxazinyl-Substituted Thienylsulphonylaminocarbonyl Compounds GESING ERNST R F 2008-12-04 — — US disclosed
EP-1773825-B1 DIOXAZINYL-SUBSTITUTED THIENYLSULPHONYLAMINOCARBONYL COMPOUNDS BAYER CROPSCIENCE AG (DE) 2008-01-23 — — EP disclosed
CN-1980921-A Dioxazinyl-substituted thienylsulfonylaminocarbonyl compounds BAYER CROPSCIENCE AG (DE) 2007-06-13 — — CN disclosed
WO-2006012982-A1 DIOXAZINYL-SUBSTITUTED THIENYLSULPHONYLAMINOCARBONYL COMPOUNDS BAYER CROPSCIENCE AG (DE) 2006-02-09 — — WO disclosed
EP-1000932-B9 AROMATIC RING DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-12-28 — — EP disclosed
EP-1000932-B1 AROMATIC RING DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2004-09-15 — — EP disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 — — US disclosed
EP-1216238-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck Frosst Canada & Co. (CA) 2002-06-26 — — EP disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 — — US disclosed
US-6242474-B1 SULFONYLCARBAMOYLALKYLIMIDAZOLE DERIVATIVES; ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-06-05 — — US disclosed
WO-2001019814-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA & CO. (CA) 2001-03-22 — — WO disclosed
EP-1000932-A1 AROMATIC RING DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-05-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022255-A1 SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE ENDOD1, CNBP, DPP4 CYP2D6 772/4885CYP2C9 1930/4885CYP2C19 1172/4885
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT CYP2D6 3694/4885CYP2C9 4407/4885CYP2C19 3796/4885
US-20080300138-A1 Dioxazinyl-Substituted Thienylsulphonylaminocarbonyl Compounds DDT, DHX35, DHX15 CYP2D6 91/4885CYP2C9 99/4885CYP2C19 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.